Invest in

Drug-Patent Cliffs

9.8%
6.0%
0.8%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
9.8%
6.0%
0.8%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 6.8%
19.8% Taro Pharmaceutical Industries Ltd. TARO 19.6%
19.4% Dr. Reddy's Laboratories Ltd RDY 9.4%
14.1% Mylan N.V. MYL 13.3%
11.6% Akorn Inc. AKRX 16.5%
9.8% Abbott Laboratories ABT 28.6%
7.7% The Medicines Company MDCO 14.8%
5.9% Impax Laboratories Inc. IPXL 45.1%
3.3% Lannett Co Inc LCI 22.9%
3.2% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 34.1%
2.8% Mallinckrodt plc MNK 20.0%
1.2% Cambrex Corporation CBM 23.0%
1.1% Endo International PLC ENDP 24.6%

Quotes delayed 15 mins. Currently Jun 23, 2017 2:51:41 PM. Fields are marked with -- when data is unavailable.